Orphagen's ACC therapy receives FDA rare pediatric disease
Orphagen has received a rare pediatric disease designation for OR-449 from the US Food and Drug Administration (FDA) to treat paediatric ACC.
Source: pharmaceutical-technology.com
Scott Thacher News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Scott Thacher. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Scott Thacher Today - Breaking & Trending Today
Orphagen Pharmaceuticals Presents Data on Downstream Targets of SF-1 Antagonist OR-449 at ENDO 2022
SAN DIEGO--(BUSINESS WIRE)--Orphagen Pharmaceuticals, an early-stage biopharmaceutical company focused on developing and commercializing novel therapies for cancer and other serious diseases with significant unmet need, today announced that additional data from its preclinical program to develop OR-449 for the treat...
Source: pharmiweb.com